DexCom, Inc.'s Stock Analysis

DexCom Reports Fourth Quarter and Fiscal Year 2025 Results

DexCom, Inc. announced preliminary, unaudited financial results for the fourth quarter and fiscal year 2025, reporting total revenue of approximately $1.260 billion for Q4, a 13% increase from the same quarter in 2024. The U.S. revenue is expected to be around $892 million, while international revenue is projected at approximately $368 million. For the full fiscal year 2025, total revenue is estimated at about $4.662 billion, reflecting a 16% growth compared to 2024. The company reiterated its non-GAAP gross profit margin guidance of approximately 61% and non-GAAP operating margin guidance of 20-21% for 2025.

Looking ahead to fiscal year 2026, DexCom anticipates total revenue between $5.16 billion and $5.25 billion, indicating an expected growth of approximately 11-13% over 2025. The company estimates a non-GAAP gross profit margin of around 63-64% and a non-GAAP operating margin of approximately 22-23%. DexCom's President and CEO, Jake Leach, emphasized ongoing innovation and market expansion as key drivers for growth, including the launch of new sensor technology and increased product availability to better serve the diabetes community.

Jan 12, 2026 07:30:45

DexCom Appoints New CEO and Details Executive Compensation

DexCom, Inc. has announced the appointment of Jacob S. Leach as the new President and Chief Executive Officer, effective January 1, 2026, following the resignation of Kevin R. Sayer. Leach has been serving as the interim principal executive officer since Sayer's medical leave of absence, which is expected to conclude in March 2026. Mark Foletta will continue as the interim Chairman of the Board until Sayer's return.

In connection with his promotion, Leach has entered into an offer letter that includes an annual base salary of $1,150,000, along with a target annual bonus opportunity of 150% of his base salary. He will also receive restricted stock units valued at $7,500,000, which will vest over three years, and performance stock units with a target fair value of $7,500,000, contingent on meeting specific performance conditions. Leach will remain eligible for the company's severance plan and employee benefit programs.

Dec 22, 2025 16:35:12

DexCom Reports 22% Revenue Growth in Q3 2025 Results

DexCom, Inc. reported its financial results for the third quarter of 2025, showing a revenue increase of 22% year-over-year to $1.209 billion. U.S. revenue grew by 21%, while international revenue experienced a 22% increase. The company reported a GAAP operating income of $242.5 million, representing 20.1% of revenue, which is an increase from 15.3% in the same quarter of the previous year. Non-GAAP operating income also rose to $272.9 million, or 22.6% of reported revenue, up from 21.3% in Q3 2024.

In addition to its financial performance, DexCom announced an update to its full-year 2025 guidance, raising its revenue forecast to between $4.630 billion and $4.650 billion. The company also highlighted several strategic initiatives, including the launch of an AI-powered meal logging feature and the expansion of access to its Dexcom G7 product in Canada. As of September 30, 2025, DexCom had $3.32 billion in cash and cash equivalents, indicating strong liquidity to support future growth and operational strategies.

Oct 30, 2025 16:02:39

DexCom Appoints New Director Euan Ashley to Board

On October 24, 2025, DexCom, Inc. announced the appointment of Dr. Euan Ashley to its Board of Directors. Following the increase in the Board's size to ten directors, Dr. Ashley will serve a term that expires at the 2026 Annual Meeting. He has been appointed to both the Nominating and Governance Committee and the Technology Committee, with Kyle Malady stepping down from the Nominating Committee but remaining as chair of the Technology Committee. Dr. Ashley's appointment comes with an initial equity grant of restricted stock units valued at $500,000, vesting over three years, and he will also be eligible for an annual equity grant of $345,000 at the 2026 Annual Meeting.

Dr. Euan Ashley is currently the Chair of the Department of Medicine at Stanford University and has extensive experience in healthcare research and biotechnology. His background includes founding multiple biotech companies and serving in leadership roles at Stanford, enhancing his expertise in precision medicine and healthcare innovation. His appointment is expected to provide strategic guidance for DexCom as it continues to develop its biosensing technology and advance metabolic health solutions.

Oct 27, 2025 16:15:56

DexCom CEO Takes Medical Leave; Interim Leadership Appointed

Kevin R. Sayer, the Chief Executive Officer and Chairman of DexCom, is taking a temporary medical leave of absence effective September 14, 2025. In his absence, Jacob S. Leach, currently the President and Chief Operating Officer, has been appointed as the interim principal executive officer. Additionally, Mark Foletta, the Lead Independent Director, will serve as the interim chairman of the Board.

Both Mr. Leach and Mr. Foletta will continue in their current roles without receiving additional compensation for their interim positions. There are no disclosed arrangements regarding Mr. Leach’s selection as an officer, and there are no family relationships or material interests in transactions that would require disclosure under SEC regulations.

Sep 15, 2025 19:30:47

DexCom Reports Q2 2025 Financial Results and CEO Transition

DexCom, Inc. reported a 15% year-over-year revenue increase for the second quarter of 2025, totaling $1.157 billion. The company's U.S. revenue also grew by 15%, while international revenue increased by 16%. GAAP operating income rose to $212.6 million, representing 18.4% of revenue, an improvement from the previous year. The company has raised its fiscal year 2025 revenue guidance to between $4.600 billion and $4.625 billion, maintaining its non-GAAP gross profit margin and operating margin targets.

In a significant leadership change, Kevin R. Sayer will retire as CEO on January 1, 2026, transitioning to Executive Chairman. Jacob S. Leach, currently President and Chief Operating Officer, will take over as CEO and join the Board of Directors. Leach has been with DexCom for 21 years, holding various roles that have prepared him for this leadership position. The Board has also expanded to ten directors effective January 1, 2026, as part of the succession plan.

Jul 30, 2025 16:02:50

Dexcom Promotes Jake Leach to President and COO

DexCom, Inc. has announced the promotion of Jake Leach to the position of president while retaining his role as chief operating officer. Leach, who has over 21 years of experience at Dexcom, has been instrumental in the development of the company's biosensing platforms since their inception. In his new role, he will also oversee corporate development and strategy in addition to his existing responsibilities in product development and executive leadership functions.

Kevin Sayer, the chairman and CEO of Dexcom, expressed confidence in Leach's leadership and the company's future. Leach emphasized the potential of Dexcom to address significant global health challenges and improve the lives of its customers and stakeholders. This leadership change may influence investor sentiment as it highlights the company's strategic direction and commitment to innovation in glucose management technology.

May 13, 2025 08:31:00

Dexcom Announces $750 Million Share Repurchase Program

Dexcom, Inc. reported financial results for the first quarter of 2025, with revenue reaching $1.036 billion, a 12% increase from the previous year. The company experienced a 15% growth in U.S. revenue and a 7% growth in international revenue. GAAP operating income was $133.7 million, reflecting a year-over-year increase, while non-GAAP operating income was slightly lower compared to the same quarter in 2024. The company also secured broader insurance coverage in the U.S. for its continuous glucose monitoring systems and received FDA clearance for its new Dexcom G7 15 Day System shortly after the quarter ended.

Additionally, Dexcom announced a $750 million share repurchase program, which is expected to provide financial flexibility. The company updated its fiscal year 2025 guidance, projecting revenue of $4.60 billion, representing a 14% growth. Non-GAAP gross profit margin is anticipated to be around 62%, reflecting some cost increases due to supply chain dynamics. As of March 31, 2025, Dexcom reported $2.70 billion in cash and marketable securities, indicating a strong liquidity position.

May 01, 2025 16:03:07

Dexcom Appoints New Board Member Renée Galá Amid Growth Plans

DexCom, Inc. has appointed Renée Galá to its Board of Directors, effective March 6, 2025. Galá brings extensive experience in financial and operational leadership from her current role as President and COO of Jazz Pharmaceuticals, which reported over $4 billion in revenues for 2024. Her background includes overseeing global operations and strategic initiatives, which is expected to benefit Dexcom as it aims to enhance metabolic health for its users.

The press release highlights Galá's previous positions, including CFO roles at Jazz Pharmaceuticals and GRAIL, Inc., and her tenure at Theravance Biopharma. While the announcement focuses on the positive aspects of her appointment, there are no specific financial metrics or updates regarding Dexcom's current performance or challenges mentioned in the release.

Mar 10, 2025 08:31:23

Dexcom Reports $1.114 Billion Revenue for Q4 2024

Dexcom, Inc. reported a revenue increase of 8% year-over-year, reaching $1.114 billion in the fourth quarter of 2024. The company's U.S. revenue grew by 4%, while international revenue saw a more significant increase of 17%. Additionally, Dexcom achieved a GAAP net income of $151.7 million, although this represented a decline compared to the previous year. The company also successfully launched new products and expanded its market presence, including securing reimbursement for its Dexcom ONE+ system in France and submitting its G7 product for FDA review.

On the downside, Dexcom's operating income decreased both on a GAAP and non-GAAP basis, with GAAP operating income at $188.9 million, down from $216.9 million in Q4 2023. The gross profit margin also fell, with GAAP gross profit at 58.9% of revenue compared to 63.5% in the previous year. Furthermore, net income per diluted share decreased to $0.38, down from $0.62 in Q4 2023, indicating challenges in maintaining profitability despite revenue growth.

Feb 13, 2025 16:03:33